10 recruiting, 3 active not recruiting, 2 completed, 2 terminated. 18 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 18 | Recruiting 10, Active not recruiting 3, Completed 2, Terminated 2, Withdrawn 1 |
| Phase 2 | 8 | Recruiting 5, Active not recruiting 1, Terminated 1, Withdrawn 1 |
Follow Mezigdomide: new trials by email Literature Review of Mezigdomide trials Research Report on Mezigdomide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML Ziftomenib, Mezigdomide - KMT2A-rearranged, NPM1-mutant Refractory or Relapsed AML | Phase 1 | Recruiting | Massachusetts General Hospital | 24 | 2026-09-02 | 2026-10-08 |
| A Study of Revumenib and Mezigdomide in People With Leukemia Revumenib, Mezigdomide - Leukemia, Acute Leukemia | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 52 | 2026-01-16 | 2026-10-20 |
| Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma Talquetamab, Mezigdomide, Dexamethasone - Relapsed Refractory Multiple Myeloma (RRMM) | Phase 1 | Recruiting | Massachusetts General Hospital | 25 | 2025-12-19 | 2026-04-13 |
| A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma Elranatamab, Mezigdomide, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Celgene | 62 | 2025-10-07 | 2026-09-02 |
| A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma Teclistamab, Mezigdomide - Multiple Myeloma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 18 | 2025-08-08 | 2026-10-13 |
| A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations Etentamig, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | AbbVie | 602 | 2025-06-30 | 2026-10-19 |
| Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma Elranatamab, Mezigdomide, Dexamethasone - Relapsed Refractory Multiple Myeloma (RRMM) | Phase 1 / Phase 2 | Recruiting | YOUNGIL KOH | 75 | 2024-11-26 | 2025-12-03 |
| Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration, Computed Tomography - Multiple Myeloma | Phase 1 | Active not recruiting | City of Hope Medical Center | 15 | 2024-04-09 | 2026-11-09 |
| A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment Mezigdomide - Renal Impairment | Phase 1 | Completed | Celgene | 26 | 2024-03-21 | 2025-06-04 |
| A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma Alnuctamab, Mezigdomide, Dexamethasone - Multiple Myeloma | Phase 1 | Terminated | Celgene | 4 | 2024-02-27 | 2026-04-21 |
| A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma BMS-986393, Alnuctamab, Mezigdomide - Multiple Myeloma | Phase 1 | Recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 187 | 2024-02-22 | 2026-07-16 |
| Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Active not recruiting | Abdullah Khan | 12 | 2023-12-21 | 2026-05-13 |
| Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma Mezigdomide, Ixazomib, Dexamethasone - Relapsed and Refractory Multiple Myeloma | Phase 1 / Phase 2 | Withdrawn | Kathleen Dorritie | 2023-10-02 | 2024-11-19 | |
| A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma Cohort A1 & A2: KTX-1001, Cohort B1 & B2: KTX-1001+Mezigdomide, Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®) - Multiple Myeloma, Myeloma | Phase 1 | Recruiting | K36 Therapeutics, Inc. | 165 | 2023-02-22 | 2026-10-22 |
| A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment Mezigdomide - Hepatic Impairment | Phase 1 | Completed | Bristol-Myers Squibb | 32 | 2023-02-20 | 2024-02-07 |
| A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) CC-92480, Bortezomib, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Active not recruiting | Celgene | 424 | 2019-09-30 | 2024-11-29 |
| A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) CC-92480, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Celgene | 200 | 2018-02-06 | 2026-02-09 |
| Selinexor and Backbone Treatments of Multiple Myeloma Patients Selinexor, Dexamethasone, Lenalidomide - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Karyopharm Therapeutics Inc | 300 | 2015-10-01 | 2026-07-15 |
Multiple Myeloma (14) · Recurrence (5) · Leukemia, Myeloid, Acute (2) · Kidney Failure, Chronic (1) · Leukemia (1) · Leukemia, Biphenotypic, Acute (1) · Neoplasms (1) · Neoplasms, Plasma Cell (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Renal Insufficiency (1) · Renal Insufficiency, Chronic (1)
Celgene (5) · Massachusetts General Hospital (2) · Memorial Sloan Kettering Cancer Center (2) · AbbVie (1) · Abdullah Khan (1) · Bristol-Myers Squibb (1) · City of Hope Medical Center (1) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (1) · K36 Therapeutics, Inc. (1) · Karyopharm Therapeutics Inc (1) · Kathleen Dorritie (1) · YOUNGIL KOH (1)
United States (16) · Canada (6) · Spain (4) · Greece (3) · United Kingdom (3) · Australia (2) · Denmark (2) · France (2) · Germany (2) · Israel (2) · Japan (2) · Norway (2) · South Korea (2) · Belgium (1) · China (1)
Abdullah M Khan, MBBS, MSc (1) · Amir Fathi, MD (1) · Andrew J. Yee, MD (1) · Kathleen A Dorritie, MD (1) · Kuo-Kai Chin, MD (1) · Malin Hultcrantz, MD, PhD (1) · Murali Janakiram (1)
PMID 30352784, PMID 37393120, PMID 37646702, PMID 38826786
2023 (2), 2017 (1), 2025 (1), P30CA033572 (1)